LaNova Medicines Initiates First Phase III Clinical Trial for LM-302 in China
-
2024-04-11
-
Share:
SHANGHAI, April 11th, 2024 – LaNova Medicines Ltd. announced the initiation of its first Phase III clinical trial for LM-302 (anti-Claudin 18.2 ADC) in China. This marks the first antibody-drug conjugate candidate in LaNova's pipeline to enter the pivotal clinical study.
The clinical study (CTR20240955) is a randomized, open-label, multi-center, positive-controlled Phase III trial primarily assessing the efficacy and safety of LM-302 in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma who are CLDN18.2 positive.